Claire Verschraegen, MD
Enriched profileSenior Advisor to The Ohio State University Comprehensive Cancer Center; holds the Diane Nye and Michael Rayden Chair in Innovative Cancer Research · The Ohio State University Comprehensive Cancer Center
Claire Verschraegen is Senior Advisor to The Ohio State University Comprehensive Cancer Center; holds the Diane Nye and Michael Rayden Chair in Innovative Cancer Research at The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 575 publications with 11,549 citations (h-index 55); ClinicalTrials.gov lists 22 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Claire Verschraegen, MD, is Senior Advisor to The Ohio State University Comprehensive Cancer Center. The public record shows 575 publications with 11,549 citations (h-index 55), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Ovarian cancer diagnosis and treatment. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 2 companies, 5 NIH-funded awards (2017–2026).
- Most recent indexed publication: 2026 · The oncologist
- Top research focus: Cancer Immunotherapy and Biomarkers
- 22 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 163.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:
- Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
Sponsor: Ohio State University Comprehensive Cancer Center
- Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Sponsor: Claire Verschraegen
Industry payments
Updated 18 Oct 2026
2 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202515 payments$19,572openpaymentsdata.cms.gov ↗
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202412 payments$10,779openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.4%Hedgehog Pathway Inhibitor43.2%Odomzo72%Erivedge28%Part D<11 patientsMitogen-activated protein kinase (MEK) inhibitors9.1%Mektovi100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
28%l-Thyroxine28%Levothyroxine Sodium100%Part D≥12 patientsNervous system
10.6%Phenothiazine10.6%Prochlorperazine Maleate100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
5 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- OSU as a Network Lead Academic Participating Site for the NCI NCTN
Ohio State University
FY2026$1,100,102UG1CA233331 - OSU as a Network Lead Academic Participating Site for the NCI NCTN
Ohio State University
FY2025$1,044,921UG1CA233331
Congress activity
Updated 18 Oct 2026
90 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Anti-tumor activity of FF-10850 (liposomal topotecan) in patients with advanced Merkel cell carcinoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Clinical cancer research
Clinical Trial2023 - Impact of the Immediate Release of Clinical Information Rules on Health Care Delivery to Patients With Cancer.
JCO oncology practice
Article2023 - A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Clinical cancer research
Comment2023
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Incidence and Survival Rates for Female Malignant Germ Cell TumorsArticle391 citations2006
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/claire-verschraegen-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Université Libre de Bruxelles, Belgium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertinstitute.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertinstitute.com ↗
Editorial & leadership roles
journal and society appointments- Board of Directors member
Alliance for Clinical Trials in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertinstitute.com ↗ - Executive Committee member
Alliance for Clinical Trials in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertinstitute.com ↗ - Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertinstitute.com ↗ - Member
American Association for Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertinstitute.com ↗ - Member
American College of Physicians
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertinstitute.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Raphael Pollock, MD, PhD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD
The Ohio State University Comprehensive Cancer Center
James Blachly, MD
The Ohio State University Comprehensive Cancer Center
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute